Amylyx Pharmaceuticals Inc

For the period ended Dec 31, 2024. Filed Mar 4, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 4, 2025

AMLX$30.21+2.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share data)

	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$77,391	$170,201
Marketable securities	99,110	201,161
Accounts receivable, net	447	40,050
Inventories	—	38,323
Prepaid expenses and other current assets	12,484	14,931
Total current assets	189,432	464,666
Property and equipment, net	961	2,686
Restricted cash equivalents	1,446	719
Operating lease right-of-use assets	1,771	3,725
Long-term inventories	—	44,957
Other assets	24	701
Total assets	$193,634	$517,454
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$2,939	$22,061
Accrued expenses	23,949	57,724
Operating lease liabilities, current portion	1,518	2,257
Total current liabilities	28,406	82,042
Operating lease liabilities, net of current portion	463	1,980
Total liabilities	28,869	84,022
Commitments and contingencies (Note 16)
Stockholders’ equity:
Common stock, $0.0001 par value; 300,000,000 shares authorized; 68,629,738 and 67,707,432 shares issued and outstanding as of December 31, 2024 and 2023, respectively	7	7
Additional paid-in capital	771,542	738,177
Accumulated deficit	(606,692)	(304,949)
Accumulated other comprehensive (loss) income	(92)	197
Total stockholders’ equity	164,765	433,432
Total liabilities and stockholders' equity	$193,634	$517,454

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.